Dickinson Andrew D

CFO Dickinson sold 17,929 shares at blended $118.17 for $2.1M on 2025-03-10

Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, executed 2 separate sales totaling 17,929 shares for $2,118,695.71 on 2025-03-10 at a blended average price of $118.17. His post-transaction holdings of 173,174 shares represent a 9.4% reduction from his pre-transaction holdings of 191,103 shares. At the current price of $113.99, the sales occurred 3.6% above current market levels. The insider's same-ticker history at GILD shows 5 prior sales with mixed outcomes: 0 of 2 prior sells with measurable 90-day data were well-timed (both showed positive subsequent returns of +20.7%, indicating the stock rose after he sold). This sale follows a recent sell on 2025-02-12, continuing a pattern of regular periodic dispositions without clear evidence of anticipatory downside timing based on prior trading results.

CFO Andrew D Dickinson sold 137.7K GILD shares at $102.22 for $14.1M on 2025-02-12, reducing holdings by 44.6%

CFO Andrew D Dickinson sold 137,676 shares of Gilead Sciences for $14,073,240.72 on 2025-02-12, reducing his holdings from 308,899 shares to 171,223 shares. This represents a substantial 44.6% reduction in his stake. The sale occurred as Gilead traded at $102.22, within 3% of the 52-week high of $105.96, and follows a significant 16.4% 30-day gain in the stock. Notably, Dickinson has engaged in four prior open-market sales at Gilead over the past three months (most recently on 2025-01-31), establishing a pattern of consistent liquidation. While his cross-ticker track record shows an average 30-day return of 1.1% following prior sales, measurable 90-day outcomes at Gilead remain limited, with none yet demonstrating well-timed execution at that horizon. The unusually low P/E of 1059.60 and modest annual revenue growth of -0.6% warrant independent fundamental analysis to contextualize these ongoing portfolio reductions.

CFO Andrew D Dickinson sold 142,180 GILD shares at $97.22 on 2025-01-31 for $13.8M, reducing holdings 52.3%

CFO Andrew D Dickinson executed a substantial sale of 142,180 shares at $97.22, reducing his post-transaction holdings from 272,053 to 129,873 shares—a -52.3% reduction in stake. The stock traded at $98.38 as of the filing date, just 0.0% below its 52-week high of $98.38, suggesting the sale occurred near recent strength; price momentum over 30 and 90 days showed +7.6% and +9.0% respectively. In prior sales at GILD, the insider's 30-day outcomes were modest (+0.5% and +1.4%), and no measurable 90-day outcomes are yet available for timing assessment. With a P/E of 983.80 and flat annual revenue growth of -0.6%, the company's valuation metrics remain notable context for this large reduction in insider stake.

CFO Andrew D Dickinson sold 8,500 GILD shares at $91.96 on 2024-12-16; retains 132,373 shares.

Andrew D Dickinson, CFO of Gilead Sciences, sold 8,500 shares for a total value of $781,660.00, reducing his holdings by 6.0% to 132,373 shares. The sale occurred at $91.96 per share while the stock was trading 5.2% below its 52-week high of $97.90 and has risen 5.0% over the prior 30 days and 10.6% over 90 days. Dickinson has completed two prior sales at Gilead (both on 2024-11-29), indicating a recent pattern of share dispositions by this executive. The company reports a P/E of 928.00, which appears elevated relative to reported net income of $1,253,000,000.00 on quarterly revenue of $7,545,000,000.00. The sale represents routine portfolio management at a moderate price level rather than a strategic inflection point.

CFO Dickinson sells 248,645 shares (64.2% of holdings) for $23.1M at $92.76–$92.77

Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, executed 2 separate sales totaling 248,645 shares for $23,065,270.54 on 2024-11-29, reducing his holdings from 387,564 shares to 138,919 shares. This represents a 64.2% reduction in his shareholdings at a blended average price of $92.76, occurring when the stock is trading at $92.49 (near recent highs of $97.90). The magnitude of the reduction—nearly two-thirds of his position—is material and contrasts with the company's fundamentals of $7.5B quarterly revenue and $1.3B net income, though the elevated P/E of 924.90 reflects earnings concentration or one-time items. The sale's scale and timing relative to the stock's recent momentum (+16.9% over 90 days) requires review of any concurrent company developments or regulatory filings that may illuminate the transaction's context.